Palabras clave
Cómo citar
Resumen
Introduction: Chronic hemodialysis aims to replace renal function and provides an extension of life expectancy, however, complications do occur and they can be serious even fatal. Knowing the complications can enable a better prognostic evaluation and use of an intervention approach. These can be identified when performing anamnesis and physical examination, as well as, with greater precision, by means of renal and cardiac biomarkers and imaging tests.
Objectives: to identify valid blood biomarkers to detect heart failure and kidney failure associated with kidney disease and hemodialysis.
Methods: systematic literature review conducted in August 2018 in the following: Web Of Science, PubMed, Scopus, Cinahal, Cochrane, Science Direct and Lilacs. The guiding question was: “What are the blood biomarkers used to detect heart failure and kidney failure?” A total of 537 publications were found, 94 of these appeared more than once, 383 were excluded after reading titles and abstracts, 32 were excluded after reading the full texts, and 10 were excluded in the quantitative and qualitative synthesis.
Results: 18 papers compose the final sample and report laboratory and imaging tests, instruments to assess the risk of kidney and heart failure, and also clinical management of the progression of kidney and heart failure. All the studies correlated risk of mortality and death outcome.
Conclusion: laboratory tests are important to identifying kidney and heart failure and need to be used to improve clinical management of the hemodialysis treatment of people with chronic kidney disease in order to improve quality of life and life expectancy.
Citas
Reilly RF, Perazella MA. Nefrologia em 30 dias. 2nd ed. Artmed; 2015.
Mazur-Laskwska M, Bała-Błądzińska A, Zegartowska P, Dumnicka P, Ząbek-Adamska A, Kapusta M, et al. Serum pregnancyassociated plasma protein A correlates with inflammation and malnutrition in patients treated with maintenance hemodialysis. Folia Med Cracov. 2015 [cited 2019 Apr 21]. Available from:https://reference.medscape.com/medline/abstract/26774806.
Reis MLCA. Síndrome cardiorrenal. Arco Arquivos Centro-Oeste de Cardiologia. 2011[cited 2019 Apr 20];(4):20-3. Available from: http://sociedades.cardiol.br/co/revista_arco/2011/Revista04/08-revisao-sindrome.pdf.
Sociedade Brasileira de Nefrologia (SBN). Tratamento: Hemodiálise. SBN; 2018 [cited 2019 Apr 20]. Available from: https://sbn.org.br/publico/tratatamentos/hemodialise/.
Barberato SH, Bucharles SGE, Barberato MFA, Pecoits-Folho R. Associação entre Parâmetros Clínicos e Ecodopplercardiográficos com Morte Súbita em Pacientes de Hemodiálise. Arq Bras Cardiol. 2016. https://dx.doi.org/10.5935/abc.20160098.
Aldemar-Castro A. Revisão Sistemática e Meta-análise. Metodologia. 2001 [cited 2019 Feb 3]. Available from: http://www.usinadepesquisa.com/metodologia/wp-content/uploads/2010/08/meta1.pdf.
Galvão TF, Pansani TSA, Harrad D. Principais itens para relatar revisões sistemáticas e meta-análises: a recomendação PRISMA. Epidemiol. Serv. Saúde. 2015;24(2):335-42. http://dx.doi.org/10.5123/S1679-49742015000200017.
Oxford Centre for Evidence-Based Medicine (CEBM). The Oxford 2011 Levels of Evidence. Oxford: CEMB; 2011 [cited 2019 Feb 19]. Available from: https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf.
Malta M, Cardoso LO, Bastos FI, Magnanini MMF, da Silva CMFP. Iniciativa STROBE: subsídios para a comunicação de estudos observacionais. Rev Saúde Pública. 2010;44(3):559-65. http://dx.doi.org/10.1590/S0034-89102010000300021.
Pacheco RL, Garcia CM, Hosni ND, Latorraca COC, Martimbianco ALC, Logullo P, et al. Guidelines para publicações de estudos científicos. Parte 3: como publicar ensaios clínicos. Diagn Tratamento. 2017 [cited 2019 May 29]. Available from: http://docs.bvsalud.org/biblioref/2017/11/875481/rdt_v22n4_169-175.pdf.
Lacson Jr E, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, et al. Survival with Three-Times Weekly In-Center Nocturnal Versus Conventional Hemodialysis. J Am Soc Nephrol. 2012;23(4):687-95. http://dx.doi.org/10.1681/ASN.2011070674.
Floege J, Gillespie IA, Kronenberg F, Anker SD, Gioni I, Richards S, et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int. 2015;87(5):996-1008. http://dx.doi.org/10.1038/ki.2014.419.
Janda K, Krzanowski M, Gajda M, Dumnicka P, Fedak D, Lis GJ, et al. Cardiovascular risk in chronic kidney disease patients: intima-media thickness predicts the incidence and severity of histologically assessed medial calcification in radial arteries. BMC Nephrol. 2015;16:78. http://dx.doi.org/10.1186/s12882-015-0067-8.
Vashistha T, Streja E, Molnar MZ, Rhee CM, Moradi H, Soohoo M, et al. Red Cell Distribution Width and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2016;68(1):110-21. http://dx.doi.org/10.1053/j.ajkd.2015.11.020.
Toledo FR, Antunes AA, Vannini FCD, Silveira LVA, Martin LC, Barretti P, et al. Validity of malnutrition scores for predicting mortality in chronic hemodialysis patients. Int Urol Nephrol. 2013; 45(6):1747-53. http://dx.doi.org/10.1007/s11255-013-0482-3.
Akgul A, Bilgic A, Sezer S, Arat Z, Ozdemir FN, Haberal M. Low Total Plasma Homocysteine Level in Relation to Malnutrition, Inflammation, and Outcome in Hemodialysis Patients. J Ren Nutr. 2008;18(4):338-46. http://dx.doi.org/10.1053/j.jrn.2007.11.007.
Rocco MV, Lockridge Jr RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int. 2011;80(10):1080-91. http://dx.doi.org/10.1038/ki.2011.213.
Rivara MB, Chen CH, Nair A, Cobb D, Himmelfarb J, Mehrotra R. Indication for Dialysis Initiation and Mortality in Patients With Chronic Kidney Failure: A Retrospective Cohort Study. Am J Kidney Dis. 2017;69(1):41-50. http://dx.doi.org/10.1053/ j.ajkd.2016.06.024.
Karlsson F, Modica A, Mooe T. Association of Level of Kidney Function and Platelet Aggregation in Acute Myocardial Infarction. Am J Kidney Dis. 2009;54(2):262-9. http://dx.doi.org/10.1053/j.ajkd.2009.04.023.
Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. 2014;10(6):463-70. http://dx.doi.org/10.1016/j.nephro.2014.04.002.
Aranalde GI, Girino C, Suita GR. Utilidad del NT-probnp como marcador analítico de hipertrofia ventricular izquierda en pacientes dialíticos. Rev. Med. Rosario. 2016 [cited 2019 Apr 21]. Available from: http://www.circulomedicorosario.org/Upload/Directos/Revis- ta/aa4158Aranalde.pdf.
Thomé FS, Senger M, Garcez C, Garcez J, Chemello C, Manfro RC. Dialysis water treated by reverse osmosis decreases the levels of C-reactive protein in uremic patients. Braz J Med Biol Res. 2005;38(5):89-794. http://dx.doi.org/10.1590/S0100-879X2005000500018.
Sanchez-Perales C, Vázquez-Ruiz-de Castroviejob E, García-Cortésa MJ, Biechya MM, Gil-Cunqueroa KM, Borrego-Hinojosa J, et al. Las calcificaciones valvulares al inicio de diálisis predicen la aparición de eventos cardiovasculares en la evolución. Nefrología. 2015;35(2):125.226. http://dx.doi.org/10.1016/j.nefro.2015.05.017.
Martin RSS, Martin LC, Franco RJS, Barretti P, Caramori JCT, Castro JH, et al. Ventricular Hypertrophy and Cardiovascular Mortality in Hemodialysis Patients With Low Educational Level. Arq Bras Cardiol. 2012;98(1):52-61. http://dx.doi.org/10.1590/S0066-782X2012005000004.
Barberato SH, Bucharles SGE, de Souza AM, Costantini CO, CostantiniII; CRF, Pecoits-Filho R. Associação entre Marcadores de Inflamação e Aumento do Átrio Esquerdo em Pacientes de Hemodiálise. Arq Bras Cardiol. 2013;100(2):141-6. https://doi.org/10.5935/ abc.20130027.
Morsch C, Gonçalves LP, Barros E. Índice de gravidade da doença renal, indicadores assistenciais e mortalidade em pacientes em hemodiálise. Rev Assoc Med Bras. 2005;51(5):296-300. https://doi.org/10.1590/S0104-42302005000500023.
Quiroga B, Vega A, Abad S, Villaverde M, Reque J, López-Gómez JM. Creatine-kinase and dialysis patients, a helpful tool for stratifying cardiovascular risk? Nefrología 2016;3:51-6. https://doi.org/10.1016/j.nefroe.2016.01.010.
Li Y, Zhou C, Zhou X, Song L, Hui R. PAPP-A in cardiac and non-cardiac conditions. Clin Chim Acta. 2013;417:67-72. http://dx.doi.org/10.1016/j.cca.2012.12.006.
Pinon P, Kaski JC. Inflamación, aterosclerosis y riesgo cardiovascular: PAPP-A, Lp-PLA2 y cistatina C. ¿Nuevas aportaciones o información redundante?. Rev Esp Cardiol. 2006;59(3):247-58. http://dx.doi.org/10.1157/13086083.
Ujszaszi A, Molnar MZ, Czira ME, Novak M, Mucsi I. Renal function is independently associated with red cell distribution width in kidney transplant recipients: a potential new auxiliary parameter for the clinical evaluation of patients with chronic kidney disease. Br J Haematol. 2013;161(5):715-25. http://dx.doi.org/10.1111/bjh.12315.
Mucsi I, Ujszaszi A, Czira ME, Novak M, Molnar MZ. Red cell distribution width is associated with mortality in kidney transplant recipients. Int Urol Nephrol. 2014;46(3):641-51. http://dx.doi.org/10.1007/s11255-013-0530-z.
Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJV, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50(1):40-7. http://dx.doi.org/10.1016/j.jacc.2007.02.067.
Lu YA, Fan PC, Lee CC, Wu VCC, Tian YC, Yan CW, et al. Red cell distribution width associated with adverse cardiovascular outcomes in patients with chronic kidney disease. BMC Nephrology. 2017;18(1):361. http://dx.doi.org/10.1186/s12882-017-0766-4.
Hsieh YP, Chang CC, Kor CT, Yang Y, Wen YK, Chiu PF. The Predictive Role of Red Cell Distribution Width in Mortality among Chronic Kidney Disease Patients. PLOS ONE. 2016;11(12):e0162025. http://dx.doi.org/10.1371/journal.pone.0162025.
Canadas-Garre M, Anderson K, McGoldrick J, Maxwell AP, McKnight, AJ. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. J Proteomics. 2019;193:93-122. http://dx.doi.org/10.1016/j.jprot.2018.09.020.
Ahmed KAA, Al-Attab WM. Prognostic performance of combined use of high- sensitivity troponin T and creatine kinase MB isoenzyme in high cardiovascular risk patients with end-stage renal disease. Kidney Res Clin Pract. 2017;36(4):358-67. http://dx.doi.org/10.23876/j.krcp.2017.36.4.358.
Odum EP, Wakwe VC. Clinical Significance of Creatine Kinase-MB Elevation in Patients with Chronic Kidney Disease before Initiation of Hemodialysis. Cardiology and Angiology: Na International Journal. 2017;6(4):1-7. https://doi.org/10.9734/CA/2017/38020.
Chen M, Arcari L, Engel J, Freiwald T, Platschek S, Zhou H, et al. Aortic stiffness is independently associated with interstitial myocardial fibrosis by native T1 and accelerated in the presence of chronic kidney disease. Int J Cardiol Heart Vasc. 2019;24:100389. http://dx.doi.org/10.1016/j.ijcha.2019.100389.
Niizuma S, Iwanaga Y, Yahata T, Miyazaki S. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med. 2017;4:10. http://dx.doi.org/10.3389/fcvm.2017.00010.
Manousopoulos K, Lykka A, Michas F, Kostogianni K, Koroboki E, Dimitriou A, et al. Association of short-term variability indices with common carotid artery intima-media thickness in chronic kidney disease patients. Journal of Hipertension. 2018;36:e70. http://dx.doi.org/10.1097/01.hjh.0000539159.96280.38.
Zhao Y, Dong Y, Wang J, Sheng L, Chai Q, Zhang H, et al. Longitudinal association of carotid endothelial shear stress with renal function decline in aging adults with normal renal function: A population-based cohort study. Sci Reps. 2019;9:2051. https://doi.org/10.1038/s41598-018-38470-x.
Sud M, Naimark DMJ. Cardiovascular disease in chronic kidney disease in 2015. Curr Opin Nephrol Hypertens. 2016;25(3):203-7. http://dx.doi.org/10.1097/MNH.0000000000000213.
Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes. Contrib Nephrool. 2017;191:32-43. http://dx.doi.org/10.1159/000479254.
Ataklte F, Song R, Upadhyay A, Ramachandran VS, Xanthakis V. Abstract 14106: Association of Mildly Reduced Estimated Glomerular Filtration Rate With Clinical and Subclinical Cardiovascular Disease and Chronic Kidney Disease: The Framingham Heart Study. Circulation. 2019 [cited 2019 May 20];140:A14106. Available from: https://www.ahajournals.org/doi/abs/10.1161/ circ.140.suppl_1.14106.
McCullough PA, Chan CT, Weinhadl ED, Burkart JM, Bakris GL. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016;68(5S1):S5-14. http://dx.doi.org/10.1053/j.ajkd.2016.05.025.
Netti GS, Rotondi M, Di Lorenzo A, Papantonio D, Teri A, Schirone M, et al. Nocturnal haemodialysis is associated with a reduced occurrence of low triiodothyronine serum levels in haemodialysed patients. Clin Kidney J. 2020;13(3):450-60. http://dx.doi.org/10.1093/ckj/sfaa003.
Graham-Brown MPM, Churchward DR, Hull KL, Preston R, Pickering WP, Eborall HC, et al. Cardiac Remodelling in Patients Undergoing in-Centre Nocturnal Haemodialysis: Results from the MIDNIGHT Study, a Non-Randomized Controlled Trial. Blood Purif. 2017;44(4):301-10. http://dx.doi.org/10.1159/000481248.
Roumeliotis A, Roumeliotis S, Chan C, Pierratos A. Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis. Curr Vasc Pharmacol. 2020. http://dx.doi.org/10.2174/1570161118666200401112106.
Gan SWS, Chan CT. CKD as CAD Equivalent: Inflammatory Milieu and Vascular Oxidative Stress. In: Rangaswami J, Lerma E, Ronco C, editors. Cardio-Nephrology. 2017 [cited 2020 May 26]. https://doi.org/10.1007/978-3-319-56042-7_6.
Shafiee MA, Chamanian P, Shaker P, Shahideh Y, Broumand B. The Impact of Hemodialysis Frequency and Duration on Blood Pressure Management and Quality of Life in End-Stage Renal Disease Patients. Healthcare (Basel). 2017;5(3):52.http://dx.doi.org/10.3390/ healthcare5030052.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Derechos de autor 2020 Revista Colombiana de Nefrología